Although the previously established biomarkers for predicting clinical outcomes of immunotherapy, such as PD1/PD-L1 expression, have not been a guarantee of success for all cancer patients, it is still important to find the most accurate and generalized predictive signatures in each patient42. This evidence concerns the gene CD274 and cancer.